---
title: "Tianjin Tianyao Pharmaceuticals Co., Ltd. (600488.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600488.SH.md"
symbol: "600488.SH"
name: "Tianjin Tianyao Pharmaceuticals Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T22:27:46.804Z"
locales:
  - [en](https://longbridge.com/en/quote/600488.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600488.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600488.SH.md)
---

# Tianjin Tianyao Pharmaceuticals Co., Ltd. (600488.SH)

## Company Overview

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company’s primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid raw materials, as well as preparations, including injections, ointments, creams, hard capsules, pills, freeze-dried powder injections, inhalation preparations, and tablets.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.kingyork.biz](https://www.kingyork.biz) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.52)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 123 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -12.97% |  |
| Net Profit YoY | -80.22% |  |
| P/B Ratio | 2.15 |  |
| Dividend Ratio | 1.63% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6562972949.15 |  |
| Revenue | 2735239847.83 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.86% | D |
| Profit Margin | 0.97% | C |
| Gross Margin | 41.97% | B |
| Revenue YoY | -12.97% | E |
| Net Profit YoY | -80.22% | E |
| Total Assets YoY | -4.14% | D |
| Net Assets YoY | -1.33% | D |
| Cash Flow Margin | 513.64% | A |
| OCF YoY | -12.97% | E |
| Turnover | 0.47 | C |
| Gearing Ratio | 30.59% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Tianjin Tianyao Pharmaceuticals Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-12.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-80.22%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.15",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.63%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6562972949.15",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2735239847.83",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.86%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.97%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "41.97%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-12.97%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-80.22%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.14%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.33%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "513.64%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-12.97%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.47",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "30.59%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 244.38 | 158/215 | 286.79 | 264.01 | 36.97 |
| PB | 2.12 | 92/215 | 1.61 | 1.54 | 1.49 |
| PS (TTM) | 2.36 | 50/215 | 1.66 | 1.58 | 1.51 |
| Dividend Yield | 1.66% | 81/215 | 2.36% | 2.30% | 2.10% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600488.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600488.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600488.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600488.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**